NCT06067490已完成1 期
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, andImmunogenicity of RC1416 Injection Via Subcutaneous Administration in Healthy Adult Volunteers.
Nanjing RegeneCore Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年6月29日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Adverse Events
研究概览
简要总结
This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.
详细描述
RC1416 is a bispecific homodimer nanobody .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 48 healthy adult subjects will be enrolled in six groups to access the safety and tolerability of single subcutaneous injection of RC1416 in healthy adult subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female aged 18 to 50 years(including the boundary value)，Chinese.
- •Male Weight of 50 kg to 90 kg，femal weight of 40kg to 90kg, and BMI of 19.0 to 28.0 kg/m2 (including the boundary value).
- •Subject have no fertility, sperm/egg donation plan for at least 6 months from the signing of the informed consent to the end of the treatment, and voluntarily takes medically recognized effective non-drug contraceptive measures (including his partner) during the trial.
排除标准
- •Have participated in clinical trials of drugs in other trials within 3 months prior to screening .
- •With clinically significant investigator-identified abnormalities of the cardiovascular, respiratory, digestive, endocrine systems (e.g., diabetes), nervous/mental systems, blood, and lymphatic systems (immune deficiency), and musculoskeletal systems.
- •With clinically significant infectious disease (e.g., cellulitis, abscess, or systemic infection (e.g., sepsis), or history of clinically significant opportunistic infection (e.g.,invasive candidiasis or pneumocystis pneumonia) within 3 months before to screening.
- •With a history of active tuberculosis or the presence of latent tuberculosis infection or active tuberculosis indicated by any current symptoms, signs or laboratory tests.
- •Have an allergic constitution, history of allergy to the test drug ingredient or to any drug or food or pollen.
- •Received chemotherapy, radiotherapy, immunosuppressive therapy, or high-dose corticosteroid treatment within 5 years before signing the informed consent.
- •Use of any prescription, OTC, traditional Chinese medicine, vitamin or health product within 1 month prior to screening;
- •Received live or attenuated vaccines within 1 month or have any vaccination schedule during the clinical trial.
- •Had surgery within 6 months prior to screening or planned surgery during the trial.
- •Have difficulty with venous blood collection, or subjects who faint at the sight of blood or a needle, or have difficulty with subcutaneous administration.
- •Have lost or donated blood for more than 400 mL(not including menstrual blood loss )or received blood transfusion or using blood products within 3 months before signing informed consent or planning to donate blood during the study or within 1 month after the trial.
- •Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 250 mL per cup) within 6 months prior to screening.
- •Have consumed any beverage or food containing grapefruit or caffeine (such as grapefruit juice, coffee, strong tea, chocolate, caffeinated carbonated beverages, cola, cocoa, etc.) in the 48 hours prior to screening.
- •Have special dietary requirements and cannot comply with a unified diet.
- •Smoked ≥5 cigarettes per day within 3 months prior to screening or or could not guarantee to quit smoking during the trial.
- •Regularly drank alcohol within 6 months prior to screening(i.e., more than 14 standard units per week for women and more than 21 standard units per week for men (1 standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) or could not abstinence during the trial; Or a positive alcohol breath test;
- •With previous history of drug abuse/drug use; Or test positive for drug abuse screening (including THC, morphine, ketamine, methamphetamine, benzodiazepines, cocaine);
- •Pregnant or lactating women, or positive blood pregnancy test results;
- •Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), human immunodeficiency virus (HIV) antigen-antibody combined detection, syphilis treponema specific antibody at the screening visit.
- •Subjects with the results of physical examination, vital signs, laboratory examination and other auxiliary examinations (chest imaging, abdominal B-ultrasonography, 12-lead electrocardiogram, etc.) were judged by the investigator as abnormal and clinically significant during the screening period.
- •The investigators considered that subjects were not suitable for this clinical trial for other reasons.
研究组 & 干预措施
RC1416
Experimental
RC1416(SAD),single ascending (25mg-600mg) of RC1416 by subcutaneous injection
干预措施: RC1416(SAD) (Drug)
Placebo
Placebo Comparator
Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.
干预措施: Placebo(SAD) (Drug)
结局指标
主要结局
Adverse Events
时间窗: up to 92 days
incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0
Vital Signs
时间窗: up to 92 days
number of praticipants with clinically notable Vital Signs according to CTCAE V5.0
Laboratory Tests
时间窗: up to 92 days
number of praticipants with clinically notable Laboratory Tests according to CTCAE V5.0
ECG
时间窗: up to 92 days
number of praticipants with clinically notable Electrocardiogram(ECG) Values according to CTCAE V5.0
Injection Site Reaction
时间窗: up to 4 days
number of praticipants with clinically notable Injection Site Reaction according to CTCAE V5.0
次要结局
- Pharmacokinetics-Cmax(up to 92 days)
- Pharmacokinetics-AUC 0-t(up to 92 days)
- Pharmacokinetics-AUC 0-inf(up to 92 days)
- Anti-Drug antibody (ADA)(up to 92 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy SubjectsHealthyNCT04920370Alexion Pharmaceuticals, Inc.97
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy SubjectsType 2 DiabetesNCT05152277Fujian Shengdi Pharmaceutical Co., Ltd.90
已完成
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy VolunteersAutosomal Dominant Polycystic KidneyNCT04908462AceLink Therapeutics, Inc.69
已完成
1 期
A Study of SHR-1707 in Healthy Young Adult and Elderly SubjectsAlzheimer's DiseaseNCT04973189Shanghai Hengrui Pharmaceutical Co., Ltd.63
Unknown
1 期
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy SubjectsHealthy SubjectsNCT04880512CSPC Ouyi Pharmaceutical Co., Ltd.102